1. Home
  2. MFC vs RLAY Comparison

MFC vs RLAY Comparison

Compare MFC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MFC
  • RLAY
  • Stock Information
  • Founded
  • MFC 1887
  • RLAY 2015
  • Country
  • MFC Canada
  • RLAY United States
  • Employees
  • MFC N/A
  • RLAY N/A
  • Industry
  • MFC Life Insurance
  • RLAY Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MFC Finance
  • RLAY Health Care
  • Exchange
  • MFC Nasdaq
  • RLAY Nasdaq
  • Market Cap
  • MFC 49.3B
  • RLAY 576.1M
  • IPO Year
  • MFC 1999
  • RLAY 2020
  • Fundamental
  • Price
  • MFC $31.78
  • RLAY $3.63
  • Analyst Decision
  • MFC Buy
  • RLAY Strong Buy
  • Analyst Count
  • MFC 1
  • RLAY 11
  • Target Price
  • MFC $51.00
  • RLAY $18.40
  • AVG Volume (30 Days)
  • MFC 2.3M
  • RLAY 1.6M
  • Earning Date
  • MFC 08-06-2025
  • RLAY 08-05-2025
  • Dividend Yield
  • MFC 3.76%
  • RLAY N/A
  • EPS Growth
  • MFC 14.95
  • RLAY N/A
  • EPS
  • MFC 1.85
  • RLAY N/A
  • Revenue
  • MFC $20,887,744,800.00
  • RLAY $7,679,000.00
  • Revenue This Year
  • MFC $35.15
  • RLAY $14.31
  • Revenue Next Year
  • MFC $5.64
  • RLAY N/A
  • P/E Ratio
  • MFC $16.46
  • RLAY N/A
  • Revenue Growth
  • MFC 9.27
  • RLAY N/A
  • 52 Week Low
  • MFC $23.30
  • RLAY $1.78
  • 52 Week High
  • MFC $33.07
  • RLAY $10.72
  • Technical
  • Relative Strength Index (RSI)
  • MFC 54.16
  • RLAY 63.22
  • Support Level
  • MFC $31.09
  • RLAY $3.10
  • Resistance Level
  • MFC $32.44
  • RLAY $3.75
  • Average True Range (ATR)
  • MFC 0.53
  • RLAY 0.23
  • MACD
  • MFC 0.02
  • RLAY 0.03
  • Stochastic Oscillator
  • MFC 72.28
  • RLAY 84.42

About MFC Manulife Financial Corporation

Manulife Financial provides life insurance, annuities, and asset management products to individuals and group customers in Canada, the United States, and Asia. Its investment management business contributes approximately 20% of its earnings and has around CAD 1.05 trillion in assets under management and administration as of the end of 2023. The US business, which primarily operates under the John Hancock brand, contributes about 27% of earnings and is mainly focused on providing insurance products for estate, business, and income protection. The Asia segment provides insurance products and insurance-based wealth accumulation products in over 11 countries and contributes around 30% of earnings. The Canadian business segment contributes approximately 23% of earnings.

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Share on Social Networks: